Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

38.78 -0.16 (-0.41%)
Streaming Delayed Price Updated: 9:56 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
From Exelixis, Inc.
Via Business Wire
Assessing Exelixis: Insights From 12 Financial Analysts
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and... 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors. 
Via Chartmill
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Analyst Expectations For Exelixis's Future
 
Via Benzinga
2 Stocks to Buy With Less Than $50
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup. 
Via Chartmill
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support... 
Via Chartmill
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors. 
Via Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
What 9 Analyst Ratings Have To Say About Exelixis
 
Via Benzinga
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.